From Ideas to Action
The HBS Kraft Precision Medicine Accelerator convenes best-in-class leaders from the business, medical, scientific, and technological communities to identify and solve challenges slowing the advancement of precision medicine, disseminate best practices and models to overcome these challenges, and, ultimately, enable the faster commercialization of high-impact innovations.
- Full model
- Review Landscape
Assess datasets developed by government institutions, academia, disease-based organizations, research foundations, and commercial entities.
- Identify Challenges
Identify barriers in data aggregation, generation, sharing, and analytics.
- Convene Leadership
Bring together the best minds from science, technology and business sectors.
- Discover Solutions
Catalyze innovative, actionable solutions to speed medical breakthroughs.
- Disseminate Findings
Broadly share lessons learned with the oncology community at-large.
- Educate Stakeholders
Ensure Accelerator outputs achieve maximum impact.
First We Gather. Next, We Solve.
The HBS Kraft Precision Medicine Accelerator is singularly focused on the advancement of precision medicine research models. We conducted an exhaustive survey of the precision medicine data aggregation landscape – the first and only of its kind – to identify priority areas where high-impact research models could greatly accelerate progress, from patient engagement to data aggregation and analytics. We also developed challenges, which draw on the wisdom of the most creative and out-of-the-box thinkers throughout the scientific community, to solve key questions slowing progress in precision medicine.
Professor Richard Hamermesh, Faculty Co-Chair, Professor Karim Lakhani
Jonathan Kraft, Dean Nitin Nohria, Robert Kraft, Kathy Giusti, Faculty Co-Chair
Dr. Jonathan Simons, President & CEO, Prostate Cancer Foundation
Standard bearers that look to tomorrow’s leaders.
The HBS Kraft Precision Medicine Accelerator was established in 2016 with a $20 million endowment from the Robert and Myra Kraft Family Foundation, Inc. and under the leadership of Foundation President Robert K. Kraft (MBA 1965) and Jonathan Kraft (MBA 1990). It leverages the unique resources of Harvard Business School, including its world-renowned case studies and top-tier faculty, as well as assets from the business, scientific and technology communities at large, to catalyze honest, engaging discussions and generate high-impact solutions in precision medicine. It is co-chaired by HBS faculty Richard Hamermesh and Kathy Giusti and a Steering Committee comprised of a dynamic, multi-disciplinary team of experts and thought leaders.